Medication Guide App
Video: Latest Treatment for Hep C.

Retapamulin

Pronunciation: RE-te-PAM-ue-lin
Class: Antibacterial agent

Trade Names

Altabax
- Ointment, topical 1% (10 mg/g)

Pharmacology

Selectively inhibits bacterial protein synthesis, inhibiting peptidyl transfer, blocking P-site interactions, and preventing normal formation of active 50S ribosomal subunits.

Slideshow: Viagra: 11 Interesting Facts That You Can't Help But Be Amazed By

Pharmacokinetics

Absorption

Systemic exposure after topical application to intact and debrided skin is low. Following twice-daily topical application, 11% of patients had measurable retapamulin concentrations with a median concentration of 0.8 ng/mL.

Distribution

Protein binding is approximately 94%.

Metabolism

In vitro studies indicate that CYP3A4 is the major enzyme responsible for the metabolism of retapamulin to numerous metabolites.

Indications and Usage

Topical treatment of impetigo caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes .

Contraindications

None well documented.

Dosage and Administration

Adults

Topical Apply a thin layer to the affected area (up to 100 cm 2 in total area) twice daily for 5 days.

Children 9 mo of age and older

Topical Apply a thin layer to the affected area (up to 2% of total BSA) twice daily for 5 days.

Storage/Stability

Store between 59° and 86°F.

Drug Interactions

CYP3A4 inhibitors (eg, ketoconazole)

Retapamulin plasma levels may be increased; however, dosage adjustments are unnecessary.

Adverse Reactions

CNS

Headache (2%).

Dermatologic

Eczema (1%).

EENT

Nasopharyngitis (2%).

GI

Diarrhea (2%); nausea (1%).

Local

Application-site irritation, application-site pruritus (2%).

Precautions

Pregnancy

Category B .

Lactation

Undetermined.

Children

Safety and efficacy not established in children younger than 9 mo of age.

Superinfection

May promote overgrowth of nonsusceptible microorganisms.

Local effects

If sensitization or severe local irritation occurs, discontinue use and wipe off ointment.

Mucosal or systemic use

Not intended for ingestion; oral, intranasal, ophthalmic, or intravaginal use; or use on mucosal surfaces.

Overdosage

Symptoms

Not reported.

Patient Information

  • Advise patient that product is not intended for ingestion; oral, intranasal, ophthalmic, or intravaginal use; or use on mucosal surfaces (eg, lips, mouth, inside nose).
  • Advise patient that treated area may be covered by a sterile bandage or gauze dressing, if desired.
  • Instruct patients to use product for the full time recommended by health care provider, even if symptoms have improved.
  • Instruct patients to notify health care provider if there is no improvement in symptoms within 3 to 4 days of starting treatment.
  • Instruct patients to notify health care provider if irritation, redness, itching, burning, swelling, blistering, or oozing worsens in the area applied.

Copyright © 2009 Wolters Kluwer Health.

Hide
(web2)